December 15 2010 Volume 82 Number 12 wwwaafporgafp American Family Physician 1491Diagnosis Initial Management Prevention Meningitis DAVID BAMBERGER MD University MissouriKansas City School Medicine Kansas City Missouri Acute meningitis medical emer gency potential high mor bidity mortality Bacterial meningitis life threatening must distinguished common aseptic viral meningitis increased use conjugate vaccine annual incidence bacterial meningitis United States declined 19 15 case per 100000 person 1998 2003 overall mortality rate 156 percent13 Incidence rate developing country remain significantly higher Etiology Age immunosuppression neurosurgical procedure increase likelihood infec tion specific pathogen Table 1 34 person communityacquired men ingitis aseptic meningitis significantly common bacterial meningitis 96 percent child cerebrospinal fluid CSF pleocytosis aseptic meningitis5 common etiology aseptic men ingitis enterovirus herpes simplex virus HSV Borrelia burgdorferi infection adult incidence aseptic meningitis 76 case per 100000 person common etiology enterovirus HSV varicellazoster virus infections6 pathogen disease associated asep tic meningitis include Treponema pallidum Mycoplasma pneumoniae Rocky Mountain spotted fever ehrlichiosis mumps lympho cytic choriomeningitis virus acute ret roviral syndrome associated human immunodeficiency virus HIV infection Patients mosquitoborne arboviral infection eg West Nile virus St Louis encephalitis California encephali ti group often present encephalitis however may present meningeal involvement alone neurologic man ifestations Seasonality important predicting likelihood aseptic menin gitis enteroviral arbovi ral infection occur summer fall temperate climate Tuberculous fungal meningitis le common United States usually produce chronic symptom Cryptococcal meningitis com mon patient altered cellular immu nity especially advanced HIV infection eg CD4 cell count le 200 cell per mm3 200 109 per L Clinical Presentation adult communityacquired bacte rial meningitis 25 percent recent otitis sinusitis 12 percent pneumonia Although annual incidence bacterial meningitis United States declining remains medical emer gency potential high morbidity mortality Clinical sign symptom unreliable distinguishing bacterial meningitis common form aseptic meningitis therefore lumbar puncture cerebro spinal fluid analysis recommended Empiric antimicrobial therapy based age risk factor must started promptly patient bacterial meningitis Empiric therapy delayed even lumbar puncture performed result computed tomography scan pending patient awaiting transfer Concomitant therapy dexamethasone initiated time antimicrobial therapy demonstrated improve morbidity mortality adult Streptococcus pneumoniae infection Within United States almost 30 percent strain pneumococcus common etiologic agent bacterial meningitis susceptible penicillin Among adult developed country mortality rate bacterial meningitis 21 percent However use conjugate vaccine reduced incidence bacterial meningitis child adult Fam Physician 2010821214911498 Copyright 2010 American Academy Family Physicians Patient Information handout pneumo coccal conjugate vaccine available httpfamily doctororg691xml Downloaded American Family Physician Web site wwwaafporgafp Copyright 2010 American Academy Family Physicians private noncommer cial use one individual user Web site right reserved Contact copyrightsaafporg copyright question andor permission requestsMeningitis 1492 American Family Physician wwwaafporgafp Volume 82 Number 12 December 15 201016 percent immunocompromised7 Typical clinical feature listed Table 2 7 least one cardinal feature fever neck stiffness altered mental status present 99 100 percent patient meningi ti headache included two four feature observed 95 percent patient meningitis78 Kernig Brudzinski sign poorly sensitive highly specific bacterial meningitis9 Sixtythree per cent patient meningococcal meningitis present rash usually petechial7 Petechial rash may also caused Haemophilus influenzae Streptococ cu pneumoniae infection Pneumococcal meningitis likely meningococcal meningitis associ ated seizure focal neurologic finding altered consciousness Compared younger adult person 65 year older bacterial meningitis le likely headache nausea vomiting nuchal rigidity likely seizure hemiparesis10 Simi larly classical feature bacterial meningitis observed often younger child may present subtle finding lethargy irritability11 recent history upper respiratory tract infection common child bacterial meningitis chil dren also likely adult experience sei zure12 illness course varies progression hour several day clinical feature nonspe cific example study 297 adult went lumbar puncture suspected meningitis 80 27 percent degree CSF pleocytosis 20 67 percent white blood cell count 100 cell per µL 010 109 per L higher three 1 per cent cultureconfirmed bacterial meningitis9 Initial Evaluation Given lack specificity clinical finding key diagnosis meningitis evaluation CSF13 peripheral white blood cell count alone help ful distinguishing bacterial aseptic meningitis Table 1 Common Etiologies Bacterial Meningitis Recommended Empiric Therapy Population Likely pathogen Empiric therapy Infants younger one month Streptococcus agalactiae group B streptococcus Listeria monocytogenes Escherichia coli gramnegative bacilliAmpicillin cefotaxime Claforan Children one 23 month age Streptococcus pneumoniae Neisseria meningitidis agalactiae Haemophilus influenzae E coliVancomycin ceftriaxone Rocephin Children adult two 50 year ageN meningitidis pneumoniae Vancomycin ceftriaxone Adults older 50 year altered cellular immunity alcoholismS pneumoniae N meningitidis L monocytogenes aerobic gram negative bacilliVancomycin ceftriaxone ampicillin Patients basilar skull fracture cochlear implantS pneumoniae H influenzae group betahemolytic streptococci Vancomycin ceftriaxone Patients penetrating trauma postneurosurgeryStaphylococcus aureus coagulasenegative staphylococci aerobic gramnegative bacillus including Pseudomonas aeruginosaVancomycin cefepime Maxipime Patients cerebrospinal fluid shuntCoagulasenegative staphylococci aureus aerobic gramnegative bacillus including P aeruginosa Propionibacterium acnesVancomycin cefepime 20022003 among age group United States 61 percent bacterial meningitis caused pneumoniae 16 percent N meningitidis 14 percent agalactiae group B streptococcus 7 percent H influenzae 2 percent L monocytogenes 3 Adapted permission Tunkel AR Hartman BJ Kaplan SL et al Practice guideline management bacterial meningitis Clin Infect Dis 20043991275 additional information reference 3 Table 2 Clinical Laboratory Findings Adults Bacterial Meningitis Clinical laboratory featureSensitivity Two following feature fever neck stiffness altered mental status headache95 Cerebrospinal fluid white blood cell count 100 per µL 010 109 per L 93 Headache 87 Neck stiffness 83 Fever 1004F 38C 77 Nausea 74 Altered mental status Glasgow Coma Scale score 1469 Growth organism blood culture 66 Triad fever neck stiffness altered mental status44 Focal neurologic sign 33 Seizure 5 Papilledema 3 Information reference 7Meningitis December 15 2010 Volume 82 Number 12 wwwaafporgafp American Family Physician 1493particularly young child ie normal white blood cell count rule bacterial meningitis14 Men ingitis suspected patient feature previously noted fully explained diagnosis Lumbar puncture safe procedure although postprocedure headache occurs one third patients15 video lumbar puncture available httpcontentnejmorgcgicontentshort35513e12 concern lumbar puncture poorly quanti fied risk herniation patient spaceoccupying lesion severe diffuse cerebral swelling degree risk recognized previous computed tomography scan Lifethreatening herniation lum bar puncture reported patient neurologically unremarkable procedure16 Based patient series17 guidelines418 patient risk factor occult intracranial abnormality undergo computed tomography brain lumbar puncture includes patient central nervous system disease including CSF shunt hydro cephalus trauma spaceoccupying lesion recent neurosurgery immunocompromised state papilledema focal neurologic sign adult newonset sei zures moderately severely impaired consciousness Figure 141618 initial evaluation patient suspected meningitis diagnostic therapeutic maneuver begin concomitantly computed tomography scan required lumbar puncture blood culture obtained followed prompt initiation empiric antimicrobial therapy scan Adjunctive therapy dexamethasone added adult suspected pneumoniae infection19 CSF obtained Gram stain result white red blood cell count glucose level protein Initial Management Suspected Acute Meningitis Figure 1 Algorithm initial management suspected acute meningitis CSF cerebrospinal fluid Information reference 4 16 18Includes CSF shunt hydrocephalus trauma spaceoccupying lesion recent neurosurgery immunocompromised state papilledema focal neurological signsPatient present suspected meningitis Initiate droplet precaution Adequate respiratory circulatory status likely normal coagulation status based history physical examination Central nervous system disease adult newonset seizure moderately severely impaired level consciousness delay ability perform lumbar puncture41618Initiate therapy respiratory circulatory coagulation status Perform lumbar puncture blood culture Obtain blood culture initiate antimicrobial therapy patient adult likely pneumonococcal meningitis initiate concomitant dexamethasone Perform computed tomography magnetic resonance imaging CSF suggestive bacterial meningitisPerform lumbar puncture Reconsider diagnosis based clinical laboratory radiographic findingsSuspicion bacterial meningitis remains high based young age neutropenia immunosuppression evidence meningococcal meningitis Continue therapyInitiate continue antimicrobial therapy Initiate concomitant dexamethasone adult likely pneumonococcal meningitisReconsider diagnosisYesNo Yes Scan reveals mass effect cerebral edemaSpinal fluid cloudy Meningitis likely Reconsider diagnosisCSF suggestive bacterial meningitis Yes YesNo Yes Continue therapy NoANo NoGo YesYesYesMeningitis 1494 American Family Physician wwwaafporgafp Volume 82 Number 12 December 15 2010levels evaluated immediately Although single measure diagnostic combination abnormal CSF finding highly suggestive meningitis help ful determining likely etiology Table 3 Rarely patient bacterial meningitis may present mal nearnormal white blood cell count glucose lev el protein level observed young child neutropenia immunocompro mised state early course meningococ cal meningitis20 Lack CSF leukocytosis normal CSF glucose level also common patient HIV infection cryptococcal meningitis CSF cryptococcal antigen test highly sensitive specific Patients partially treated bacterial meningitis Listeria infection may CSF profile similar aseptic meningitis child received previous antimicrobial agent clinical decision rule useful identifying low risk bac terial meningitis otherwise clinically stable eligible careful observation without antimicrobial therapy Table 4521 Bacterial Meningitis Initial empiric therapy bacterial meningitis based patient age risk factor clinical feature Table 1 34 patient suspected bacterial men ingitis empiric therapy delayed one hour awaiting diagnostic testing Table 4 Clinical Decision Rules Distinguish Bacterial Aseptic Meningitis Children CSF Pleocytosis Rule Bacterial Meningitis Score 5Meningitest 21 Exclusion criterion Neurosurgical history Immunosuppression CSF red blood cell count 001 106 per µL 001 1012 per L Antibiotic use previous 48 hour PurpuraNeurosurgical history Immunosuppression CSF red blood cell count 001 106 per µL Antibiotic use previous 48 hour Criteria evaluation including lumbar puncture needed patient one findingsPositive CSF Gram stain Seizure Blood neutrophil count 10000 per µL 1000 109 per L CSF neutrophil count 1000 per µL 100 109 per L CSF protein level 80 mg per dL 080 g per L Positive CSF Gram stain Seizure Purpura Toxic appearance irritability lethargy low capillary refill CSF protein level 50 mg per dL 050 g per L Serum procalcitonin level 05 ng per mL Sensitivity 95 confidence interval 99 percent 99 100 100 percent 96 100 CSF cerebrospinal fluid White blood cell count 10 per µL 001 109 per L Adapted permission Dubos F Martinot Gendrel Bréart G Chalumeau Clinical decision rule evaluating meningitis child Curr Opin Neurol 2009223292 additional information reference 5Table 3 Typical CSF Parameters Patients Meningitis PathogenWhite blood cell per µL 109 per LPercentage neutrophil Glucose levelProtein level mg per dL g per LLikelihood observing organism CSF stain Pyogenic Listeria monocytogenes 500 050 80 Low 100 100 70 percent L monocytogenes 100 010 50 Normal 50 050 30 percent Partially treated pyogenic 100 50 Normal 70 070 60 percent Aseptic often viral 10 1000 001 100Early 50 Late 20Normal 200 200 applicable Tubercular 50 005 500 30 Low 100 Rare Fungal 50 500 30 Low Varies Often high cryptococcus CSF cerebrospinal fluidMeningitis December 15 2010 Volume 82 Number 12 wwwaafporgafp American Family Physician 1495transfers4182223 Although prospective comparative trial performed observational study found delay therapy little two six hour associated adverse outcomes2223 Factors associ ated delay antimicrobial therapy include failure receive antimicrobial transfer another facility performance head computed tomography lumbar puncture antimicrobial administra tion absence cardinal feature fever neck stiffness altered mental status admin istered antimicrobial therapy initiated con comitant use dexamethasone four day shown reduce mortality improve neurologic come adult pneumoniae infection19 shown improve outcome patient group Studies patient developing world high likelihood HIV infection shown clear benefit adjunctive dexamethasone pyogenic bac terial meningitis2425 Fluid management includes treat ment possible dehydration hyponatremia syndrome inappropriate antidiuretic hormone result Gram stain culture sus ceptibility test available specific therapy targeting pathogen administered Table 5 41116182627 Blood culture drawn antimicrobial administra tion positive 61 66 percent patients57 Initia tion antimicrobial lumbar puncture decrease yield CSF culture likelihood low CSF Table 5 PathogenSpecific Therapy Common Causes Bacterial Meningitis Pathogen Recommended therapyAdult dosage intravenous Days therapy Alternative therapy Streptococcus pneumoniae 10 14 Meropenem Merrem moxifloxacin Avelox chloramphenicolPenicillin MIC 01 mcg per mLPenicillin 4 million unit every four hour Penicillin MIC 01 1 mcg per mLCeftriaxone Rocephin 2 g every 12 hour Penicillin MIC 2 mcg per mL Vancomycin plus 15 225 mg per kg every 12 hour Ceftriaxone 2 g every 12 hour Ceftriaxone MIC 1 mcg per mL Vancomycin plus 15 225 mg per kg every 12 hour Ceftriaxone 2 g every 12 hour Neisseria meningitidis Ceftriaxone 2 g every 12 hour Five seven Chloramphenicol meropenem moxifloxacin Haemophilus influenzae Ceftriaxone 2 g every 12 hour Seven 10 Chloramphenicol moxifloxacin Streptococcus agalactiae group B streptococcusAmpicillin plus GentamicinUsually child 14 21 Vancomycin cefotaxime Claforan Listeria monocytogenes Ampicillin without2 g every four hour 21 Trimethoprimsulfamethoxazole Bactrim Septra Gentamicin 1 2 mg per kg every eight hour Enterobacteriaceae Ceftriaxone ceftazidime Fortaz cefepime Maxipime without GentamicinVaries 21 28 Ciprofloxacin Cipro meropenem trimethoprim sulfamethoxazole Staphylococci Seven 10 day shunt removal cerebrospinal fluid sterilizationDaptomycin Cubicin linezolid Zyvox consider adding rifampinMethicillin susceptible Nafcillin 2 g every four hour Methicillin resistant Vancomycin 15 225 mg per kg every 12 hour MIC minimal inhibitory concentration Listed order likely least likely Cefotaxime may used instead Consider adding rifampin Vancomycin penetration cerebrospinal fluid may diminished concomitant dexamethasone adequate level achieved continuous infusion 60 mg per kg27 first seven 10 day Information reference 4 11 16 18 26 27Meningitis 1496 American Family Physician wwwaafporgafp Volume 82 Number 12 December 15 2010glucose level degree elevation CSF protein however markedly influence result CSF Gram stain positive 60 70 percent patients2628 Polymerase chain reaction testing CSF sensitive CSF culture particularly patient received previous antimicrobials2930 However antimi crobial susceptibility testing important treatment prevention meningitis per formed organism grown culture one series United States 28 percent pneumo cocci patient meningitis susceptible penicillin 6 percent susceptible chloram phenicol 17 percent susceptible meropenem Merrem 12 percent susceptible cefo taxime Claforan1 degree resistance administration empiric therapy vancomy cin thirdgeneration cephalosporin cefotaxime ceftriaxone Rocephin recommended result susceptibility test known Aseptic Meningitis Enteroviruses common etiologic pathogen person aseptic meningitis require specific antimicrobial therapy diagnosed CSF polymerase chain reaction testing6 always needed positive test may useful dis continuing antimicrobial initiated presumptively bacterial meningitis suggested patient sexual substance use history appropriate order serum reactive plasma reagin RPR CSF Venereal Disease Research Laboratory VDRL serum HIV antibody serum HIV polymerase chain reaction test acute HIV seroconversion serum HIV antibody test may negative time clinical presentation HSV aseptic meningitis usually selflimited infec tion must distinguished HSV encephalitis based clinical radiographic feature therapy acyclovir Zovirax lifesaving patient HSV encephalitis contrast HSV encephalitis patient HSV aseptic meningitis normal mental status neurologic function enhancement observed magnetic resonance imaging temporal lobe form HSV central nervous system disease diagnosed CSF HSV polymerase chain reaction testing Infection HSV may cause recurrent disease eg Mollaret meningitis Varicella zoster virus infection may cause aseptic meningitis absence cutaneous manifestations6 Although studied clinical trial therapy acy clovir 10 mg per kg every eight hour suggested based expert opinion Central nervous system Lyme disease treated ceftriaxone 14 28 day central nervous system syphilis treated intrave nous penicillin 10 14 day Tuberculous Cryptococcal Meningitis high index suspicion needed diagnose tubercu lous meningitis culture result often delayed stain often negative Empiric therapy may lifesaving Polymerase chain reaction testing may use ful Initial treatment combination isoniazid 5 mg per kg per day adult 10 mg per kg per day child 300 mg rifampin 10 mg per kg per day adult 10 20 mg per kg per day child 600 mg pyr azinamide 15 30 mg per kg per day 2 g eth ambutol 15 25 mg per kg per day Streptomycin 20 40 mg per kg per day 1 g used lieu ethambutol young children31 Adding dexamethasone treatment regimen improves mortality patient older 14 year tuberculous meningitis32 Cryptococcal meningitis common fungal meningitis usually occurs patient altered cellular immunity Initial treatment includes amphoteri cin B 07 10 mg per kg per day intravenously plus flu cytosine Ancobon 25 mg per kg every six hour orally33 Prognosis mortality rate adult bacterial meningitis developed country 21 percent higher patient pneumococcal disease meningo coccal disease7 Neurologic sequela include hearing loss 14 percent patient hemiparesis 4 percent7 Risk factor adverse outcome include advanced age alteration mental status admission bacteremia CSF white blood cell count le 1000 per µL 100 109 per L7 mortality rate child bacterial meningitis 3 percent incidence stroke child bacterial meningitis 3 percent34 Prevention Conjugate vaccine H influenzae type B pneu moniae initiated early childhood highly effec tive reducing incidence bacterial meningitis child also adults12 Although overall incidence pneumococcal meningitis declined use conjugate vaccine percentage menin gitis case caused nonvaccine serotypes increased percentage isolates susceptible penicillin cefotaxime1 newer conjugate vaccine Neisseria meningitidis active serogroups C W135 serogroup B recommended Meningitis December 15 2010 Volume 82 Number 12 wwwaafporgafp American Family Physician 1497children 11 18 year age freshman entering college dormitory traveler region meningococ cal disease endemic eg subSaharan Africa Mecca Saudi Arabia Hajj person comple ment component deficiencies35 Patients functional anatomic asplenia receive meningococcal pneumococcal H influenzae vaccine Patients ho pitalized N meningitidis infection meningitis uncertain etiology require droplet precaution first 24 hour treatment N meningitidis ruled Chemoprophylaxis recommendation listed Table 6 111836Table 6 Chemoprophylaxis Bacterial Meningitis Pathogen IndicationAntimicrobial agent Dosage Comments Neisseria meningitidis postexposure prophylaxisClose contact eight hour someone N meningitidis infection Contact oral secretion someone N meningitidis infection Rifampin orAdults 600 mg every 12 hour two day Children one month older 10 mg per kg every 12 hour two day Children younger one month 5 mg per kg every 12 hour two daysNot fully effective rare resistant isolates Ciprofloxacin Cipro orAdults single dose 500 mg Rare resistant isolates Ceftriaxone RocephinSingle intramuscular dose 250 mg 125 mg younger 15 year Haemophilus influenzae postexposure prophylaxisLiving household one unvaccinated incompletely vaccinated child younger 48 month Rifampin 20 mg per kg per day 600 mg per day four day Streptococcus agalactiae group B streptococcus woman intrapartum periodPrevious birth infant invasive agalactiae infection Colonization 35 37 week gestation Bacteriuria pregnancy High risk fever amniotic fluid rupture 18 hour delivery 37 week gestationPenicillin G orInitial dose 5 million unit intravenously 25 3 million unit every four hour intrapartum period allergic penicillin Cefazolin 2 g followed 1 g every eight hoursClindamycin susceptibility must confirmed antimicrobial susceptibility testClindamycin Cleocin or900 mg every eight hour Vancomycin 15 20 mg per kg every 12 hour Information reference 11 18 36SORT KEY RECOMMENDATIONS PRACTICE Clinical recommendationEvidence rating References Evaluation cerebrospinal fluid key diagnosis meningitis Decision rule using clinical laboratory finding highly sensitive diagnosing meningitis childrenC 5 8 13 21 Patients risk factor occult intracranial abnormality undergo computed tomography brain lumbar punctureC 17 bacterial meningitis suspected empiric therapy antimicrobial delayed one hour patient awaiting diagnostic testing transfersC 4 18 22 23 Adults Streptococcus pneumoniae Mycobacterium tuberculosis infection receive concomitant dexamethasone antimicrobial therapy reduce mortality improve neurologic outcomesB 19 25 32 Conjugate vaccine pneumoniae Haemophilus influenzae type B recommended patient appropriate risk group reduce incidence bacterial meningitisB 1 2 consistent goodquality patientoriented evidence B inconsistent limitedquality patientoriented evidence C consensus disease oriented evidence usual practice expert opinion case series information SORT evidence rating system go httpwwwaafp orgafpsortxmlMeningitis 1498 American Family Physician wwwaafporgafp Volume 82 Number 12 December 15 2010The Author DAVID BAMBERGER MD professor medicine University MissouriKansas City School Medicine Address correspondence David Bamberger MD 2411 Holmes St Kansas City MO 64108 email bambergerdumkcedu Reprints available author Author disclosure Nothing disclose REFERENCES 1 Hsu Shutt KA Moore MR et al Effect pneumococcal conjugate vac cine pneumococcal meningitis N Engl J Med 20093603244256 2 Schuchat Robinson K Wenger JD et al Bacterial meningitis United States 1995 Active Surveillance Team N Engl J Med 1997 33714970976 3 Thigpen MC Rosenstein N Whitney CG et al Bacterial meningitis United States19982003 Paper presented 43rd Annual Meet ing Infectious Diseases Society America October 69 2005 San Francisco CA Abstract 65 4 Tunkel AR Hartman BJ Kaplan SL et al Practice guideline man agement bacterial meningitis Clin Infect Dis 200439912671284 5 Nigrovic LE Kuppermann N Macias CG et al Pediatric Emergency Medicine Collaborative Research Committee American Acad emy Pediatrics Clinical prediction rule identifying child cerebrospinal fluid pleocytosis low risk bacterial meningitis JAMA 200729715260 6 Kupila L Vuorinen Vainionpää R Hukkanen V Marttila RJ Kotilainen P Etiology aseptic meningitis encephalitis adult population Neurology 20066617580 7 van de Beek de Gans J Spanjaard L Weisfelt Reitsma JB Ver meulen Clinical feature prognostic factor adult bacterial meningitis published correction appears N Engl J Med 20053529950 N Engl J Med 20043511818491859 8 Attia J Hatala R Cook DJ Wong JG rational clinical examination adult patient acute meningitis JAMA 19992822175181 9 Thomas KE Hasbun R Jekel J Quagliarello VJ diagnostic accuracy Kernigs sign Brudzinskis sign nuchal rigidity adult sus pected meningitis Clin Infect Dis 20023514652 10 Cabellos C Verdaguer R Olmo et al Communityacquired bacterial meningitis elderly patient experience 30 year Medicine Bal timore 2009882115119 11 SáezLlorens X McCracken GH Jr Bacterial meningitis child Lan cet 2003361937521392148 12 Kaplan SL Clinical presentation diagnosis prognostic factor bacterial meningitis Infect Dis Clin North 1999133579594 13 Straus SE Thorpe KE HolroydLeduc J perform lumbar puncture analyze result diagnose bacterial meningitis JAMA 20062961620122022 14 Bonsu BK Harper MB Utility peripheral blood white blood cell count identifying sick young infant need lumbar puncture Ann Emerg Med 2003412206214 15 Ellenby MS Tegtmeyer K Lai Braner DA Videos clinical medicine Lumbar puncture N Engl J Med 200635513e12 16 Fitch MT van de Beek Emergency diagnosis treatment adult meningitis Lancet Infect Dis 200773191200 17 Hasbun R Abrahams J Jekel J Quagliarello VJ Computed tomography head lumbar puncture adult suspected meningi ti N Engl J Med 20013452417271733 18 Chaudhuri MartinezMartin P Kennedy PG et al EFNS guideline management communityacquired bacterial meningitis report EFNS Task Force acute bacterial meningitis older child adult published correction appears Eur J Neurol 2008158880 Eur J Neurol 2008157649659 19 de Gans J van de Beek European Dexamethasone Adulthood Bacterial Meningitis Study Investigators Dexamethasone adult bacterial meningitis N Engl J Med 20023472015491556 20 Bamberger DM Smith OJ Haemophilus influenzae meningitis adult initially normal cerebrospinal fluid South Med J 1990833 348349 21 Dubos F Martinot Gendrel Bréart G Chalumeau Clinical decision rule evaluating meningitis child Curr Opin Neurol 2009223288293 22 KøsterRasmussen R Korshin Meyer CN Antibiotic treatment delay outcome acute bacterial meningitis J Infect 2008576449454 23 Proulx N Fréchette Toye B Chan J Kravcik Delays admin istration antibiotic associated mortality adult acute bacterial meningitis QJM 2005984291298 24 Assiri Alasmari FA Zimmerman VA Baddour LM Erwin PJ Tleyjeh IM Corticosteroid administration outcome adolescent adult acute bacterial meningitis metaanalysis Mayo Clin Proc 2009845403409 25 Greenwood BM Corticosteroids acute bacterial meningitis N Engl J Med 20073572425072509 26 van de Beek de Gans J Tunkel AR Wijdicks EF Communityacquired bacterial meningitis adult N Engl J Med 200635414453 27 Ricard JD Wolff Lacherade JC et al Levels vancomycin cere brospinal fluid adult patient receiving adjunctive corticosteroid treat pneumococcal meningitis prospective multicenter observational study Clin Infect Dis 2007442250255 28 Nigrovic LE Malley R Macias CG et al American Academy Pediat rics Pediatric Emergency Medicine Collaborative Research Committee Effect antibiotic pretreatment cerebrospinal fluid profile chil dren bacterial meningitis Pediatrics 20081224726730 29 Bøving MK Pedersen LN Møller JK Eightplex PCR liquidarray detec tion bacterial viral pathogen cerebrospinal fluid patient suspected meningitis J Clin Microbiol 2009474908913 30 Chiba N Murayama SY Morozumi et al Rapid detection eight causative pathogen diagnosis bacterial meningitis real time PCR J Infect Chemother 20091529298 31 Blumberg HM et al American Thoracic SocietyCenters Disease Control PreventionInfectious Diseases Society America treat ment tuberculosis J Respir Crit Care Med 20031674603662 32 Thwaites GE Nguyen DB Nguyen HD et al Dexamethasone treatment tuberculous meningitis adolescent adult N Engl J Med 20043511717411751 33 Perfect JR Dismukes Dromer F et al Clinical practice guideline management cryptococcal disease 2010 update Infectious Diseases Society America Clin Infect Dis 2010503291322 34 Nigrovic LE Kuppermann N Malley R Bacterial Meningitis Study Group Pediatric Emergency Medicine Collaborative Research Committee American Academy Pediatrics Children bacterial menin gitis presenting emergency department pneumococ cal conjugate vaccine era Acad Emerg Med 2008156522528 35 Centers Disease Control Prevention CDC Advisory Committee Immunization Practices Revised recommenations Advisory Committee Immunization Practices Vaccinate Persons Aged 1118 Years Meningococcal Conjugate Vaccine MMWR Morb Mortal Wkly Rep 20075631794795 36 Division Bacterial Diseases National Center Immunization Respiratory Diseases Prevention perinatal group B streptococcal diseaserevised guideline CDC 2010 MMWR Recomm Rep 201059RR10136